Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dordaviprone - Chimerix

Next Previous
X
Search
Drug Profile

Dordaviprone - Chimerix

Alternative Names: NSC-350625; ONC 201; OP-10; TIC-10; TRAIL-inducing compound 10

Latest Information Update: 20 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncoceutics
  • Developer Brown University; Case Comprehensive Cancer Center; Chimerix; Fox Chase Cancer Center; Kazia Therapeutics; Ohara Pharmaceutical; Oncoceutics; Rutgers; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class 3-ring heterocyclic compounds; Antineoplastics; Imidazoles; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Endopeptidase Clp stimulants; TNF-related apoptosis-inducing ligand receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioma
  • Phase II Breast cancer; Endometrial cancer; Glioblastoma; Neuroendocrine tumours
  • Phase I/II Acute myeloid leukaemia; Colorectal cancer; Gallbladder cancer; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Cancer; Renal failure
  • Preclinical Adenocarcinoma; Biliary cancer; Liver cancer; Ovarian cancer
  • No development reported Mantle-cell lymphoma; Pancreatic cancer; Prostate cancer; Sarcoma; Small cell lung cancer; Solid tumours; Thyroid cancer

Most Recent Events

  • 13 Aug 2024 Chimerix submitted a provisional determination application to the TGA for dordaviprone for Glioma
  • 28 Jul 2024 No recent reports of development identified for preclinical development in Prostate-cancer in USA (PO)
  • 28 Jul 2024 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top